Persistence and Waning of Natural SARS-CoV-2 Antibodies Over 18 Months: Long-Term Durability of IgG Humoral Response in Healthcare Workers

INTRODUCTION

SARS-CoV-2 infection is highly protective against reinfection and symptomatic disease. However, the duration of natural immunity from prior infection remains largely unknown with very limited data on SARS-CoV-2 antibody persistence beyond 8 months.

We characterized the long-term durability of humoral response in seropositive healthcare workers (HCWs) in a 2-phase study (10 and 18 months). After a 10-month follow-up, 77% of seropositive subjects maintained seropositivity.

METHODS

We conducted this prospective study, monitoring serum IgG anti-SARS-CoV-2 titers among seropositive HCWs after the first COVID-19 pandemic wave in Spain (baseline study: April 2020). In the current research, 134 seropositive HCWs after 10 months were monitored expanding follow-up to 18 months.

Enzyme immunoassay developed by DIA.PRO (https://www.diapro.it/products/covid-19-igg-elisa/) was used to measure serum anti-nucleocapsid and anti-spike protein IgG antibody titers against SARS-CoV-2 (clinical sensitivity: 98–100%; specificity > 98%) throughout the entire study. It is noteworthy that the same assay belonging to the same badge was used to determine antibody titers. This test detects specific subunits of spike and nucleocapsid proteins, and this specificity explains why antibody titers measured in the study are not affected by vaccination (no impact in antibody titers maintaining or waning was observed, with no significant differences in slopes [Mann-Whitney U test, p = 0.17] and sero-reversion percentage between vaccinated and unvaccinated [p = 0.10]).

The global prevalence of sero-persistence was provided as a pooled probability (95% confidence interval was calculated by bootstrap estimation). Linear mixed models were used to investigate antibody waning. Assuming antibody levels fell exponentially, the natural log-transformed titers were modeled over time. Models were constructed using random intercept (individual) and slope (months since initial titer).

RESULTS

One hundred and thirty-four seropositive subjects (median age: 46.0 years; 68.7% female) completed the 18-month follow-up, with a median (IQR) [range] follow-up of 527 (523–533) [438–560] days (17.56 months) between the baseline (April 2020) and the final measurement (November 2021).

Considering that the prevalence of sero-persistence in the first follow-up period (10 months) was 76.79% (235/306), and the prevalence of sero-persistence was 59.7% (80/134) in the second follow-up period (18 months), the global sero-persistence probability, by bootstrap estimation with R = 500, was 45.92% with a 95% confidence interval between 39.03 and 52.45%.

Regarding factors associated with sero-persistence over time, maintaining seropositivity was observed more frequently in the third (p < 0.001) and second (p = 0.001) tercile of baseline levels of antibody titers (Table 1).

To project the time to loss of antibodies, we used a linear mixed baseline model to extrapolate the mean time to cross the threshold of 1.1A.U. (mean time to loss of antibodies). On average, subjects showed detectable concentrations of IgG anti-SARS-COV-2 up to 471.74 (95% CI: 432.43–511.06) days from baseline (Fig. 1).

DISCUSSION

While symptomatic SARS-CoV-2 infection following COVID-19 vaccination is not an infrequent phenomenon, re-infection after natural infection with SARS-CoV-2 is rare. This finding indicates that the immune response induced by natural infection is very effective and longer lasting than that induced by vaccination. It is, therefore, crucial to clearly understand the duration of this effective natural immune response, to optimize the vaccination strategy, especially in HCWs.
To the best of our knowledge, this is the first report to evaluate the kinetics and durability of SARS-CoV-2 antibodies over a period of 18 months, providing further insight into the nature of post-infection immunity. A significant percentage of subjects, close to 50%, maintained detectable antibody levels 18 months after infection, although with a significant decline in most. Additionally, the model predicts a mean time to loss of antibodies of 471 days (about 16 months) from baseline.

Antibody titers at baseline were the unique significant factor associated with an increased probability of maintaining detectable antibody levels over time, but we must consider that higher antibody levels have been associated with the severity of SARS-CoV-2 infection.

Limitations of the current study include the absence of neutralizing antibodies measurement, although correlation between anti-SARS-CoV-2 antibodies and neutralizing antibodies has been largely described. Additionally, we tested the longevity of antibodies against SARS-CoV-2 variants involved in the first wave of the pandemic and no other later variants, but this issue may be considered marginal to the results since no clinically relevant SARS-CoV-2 reinfection was detected in our follow-up study.

### Table 1 Demographic and Clinical Characteristics, by Seroreversion Status, and Univariate and Multivariate Logistic Regression Models for Identification Factors Associated with Seroreversion Status

|                      | Non-seroreversion (n = 80) | Seroreversion (n = 54) | P value | Univariate model OR (95% CI) | P value | Multivariate model OR (95% CI) | P value |
|----------------------|---------------------------|------------------------|---------|-----------------------------|---------|-------------------------------|---------|
| **Age (years)**      |                           |                        |         |                             |         |                               |         |
| < 45 years           | 32 (52.0%)                | 30 (48.0%)             | 0.076   | Ref.                        | –       | Ref.                          | –       |
| ≥ 45 years           | 48 (66.7%)                | 24 (33.3%)             | 0.136   | 0.53 (0.26–1.07)            | 0.078   | 0.71 (0.31–1.64)              | 0.427   |
| **Sex**              |                           |                        |         |                             |         |                               |         |
| Female               | 51 (55.4%)                | 41 (44.6%)             | 0.56    | 0.56 (0.25–1.19)            | 0.138   | 0.42 (0.17–1.08)              | 0.071   |
| Male                 | 29 (69.0%)                | 13 (31.0%)             | < 0.001 | Ref.                        | –       | Ref.                          | –       |
| **Baseline IgG anti-SARS-CoV-2 antibody titer** |                        |                        |         |                             |         |                               |         |
| T1                   | 7 (20.6%)                 | 27 (79.4%)             | < 0.001 | Ref.                        | –       | Ref.                          | –       |
| T2                   | 27 (60%)                  | 18 (40%)               | 0.06    | 0.06 (0.02–0.16)            | < 0.001 | 0.06 (0.02–0.18)              | <0.001  |
| T3                   | 45 (83.3%)                | 9 (16.7%)              |         |                             |         |                               |         |
| **Exposure risk**    |                           |                        |         |                             |         |                               |         |
| Non-high grade       | 23 (51.1%)                | 22 (48.9%)             | 0.149   | Ref.                        | –       | Ref.                          | –       |
| High grade           | 57 (64%)                  | 32 (36%)               | 0.59    | 0.59 (0.28–1.22)            | 0.151   | 0.59 (0.25–1.40)              | 0.235   |
| **COVID-19 symptoms** |                          |                        |         |                             |         |                               |         |
| Yes                  | 25 (52.1%)                | 23 (47.9%)             | 0.179   | Ref.                        | –       | Ref.                          | –       |
| No                   | 55 (64%)                  | 31 (36%)               | 0.61    | 0.61 (0.30–1.26)            | 0.181   | 0.65 (0.26–1.59)              | 0.344   |
| **Infection category** |                        |                        |         |                             |         |                               |         |
| Asymptomatic/ mild   | 66 (58.4%)                | 47 (41.6%)             | 0.479   | Ref.                        | –       | Ref.                          | –       |
| Moderate/severe      | 14 (66.7%)                | 7 (33.3%)              | 0.70    | 0.70 (0.25–1.83)            | 0.480   | 1.12 (0.30–4.24)              | 0.865   |
| No                   | 7 (87.5%)                 | 1 (12.5%)              | 0.109   | 1.41 (0.64–3.23)            | 0.400   | 1.21 (0.45 – 3.27)            | 0.704   |
| Yes                  | 73 (57.9%)                | 53 (42.1%)             |         |                             |         |                               |         |

Statistical inference was performed using chi-square test or Fisher test when needed.

COVID-19 coronavirus disease 2019, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, IgG immunoglobulin G

1. One patient was excluded because a re-infection was documented during the follow-up study.

Figure 1 Evolution of anti-SARS-CoV-2 titers over time. Linear mixed model for the SARS-CoV-2 IgG antibodies decline, with the overall mean trajectory from the mean baseline level. The mean trajectory and 95% confidence interval are shown as a solid line and shaded gray area, respectively. The dashed vertical line represents the mean time to loss of antibodies from baseline and the dashed horizontal line represents the titer threshold of 1.1 A.U.
In conclusion, the findings of our research are encouraging, demonstrating a mean durability of naturally acquired antibodies close to 16 months, suggesting a strong protective role against SARS-CoV-2 reinfection.

Acknowledgements: We are grateful to all staff who contributed to the development of the study and all healthcare workers enrolled and involved in this follow-up research.

Jose F. Varona, MD, PhD
Javier Muñiz, PhD
Vanessa Balboa-Barreiro, MD
Francisco Peñalver, MD
Elena Abarca, MD
Cristina Almirall, MD
Jose María Castellano, MD, PhD

1Departamento de Medicina Interna, Hospital Universitario HM Montepríncipe, HM Hospitales, Madrid, Spain
2Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
3Fundación de Investigación, HM Hospitales, Madrid, Spain
4Grupo de Investigación Cardiovascular, Departamento de Ciencias de la Salud e Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidad de La Coruña, A Coruña, Spain
5Unidad de Apoyo a la Investigación, Complejo Hospitalario Universitario A Coruña (CHUAC)-Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain
6Departamento de Seguridad, Salud y Bienestar de HM Hospitales, Madrid, Spain
7Servicio de Laboratorio, HM Hospitales, Madrid, Spain
8Departamento de Cardiología, Centro Integral de Enfermedades Cardiovasculares (CIEC), Hospital Universitario HM Montepríncipe, Madrid, Spain
9Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Salud Carlos III, Madrid, Spain

Corresponding Author: Jose F. Varona, MD, PhD; Departamento de Medicina Interna, Hospital Universitario HM Montepríncipe, HM Hospitales, Madrid, Spain (e-mail: jfvarona@hmhospitales.com).

Author Contribution All authors conceptualized and designed the study. J.F.V., J.M., and J.M.C. drafted the manuscript and made final revisions, and all of the authors critically revised, read, and approved the final manuscript.

Data Availability The data underlying this article will be shared on reasonable request to the corresponding author.

Declarations:

Ethics Approval: The protocol was approved by the Ethics Committee of HM Group (GHM) (Comité Ético de Investigación con Medicamentos de HM Hospitales) (ref. no. 20.04.1611/1640-GHM).

Conflict of Interest: The authors declare that they do not have a conflict of interest.

REFERENCES

1. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) [published correction appears in Lancet. 2021 May 8;397(10286):1710]. Lancet. 2021;397(10283):1459-1469. https://doi.org/10.1016/S0140-6736(21)00675-9

2. Varona JF, Madurga R, Peñalver F, et al. Kinetics of anti-SARS-CoV-2 antibodies over time. Results of 10 month follow up in over 300 seropositive health care workers. Eur J Intern Med. 2021;89:97-103. https://doi.org/10.1016/j.ejim.2021.05.028

3. Angel Y, Spitzer A, Henig O, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021;325(24):2457-2465. https://doi.org/10.1001/jama.2021.7152

4. Vitale J, Mumoli N, Clerici P, De Paschale M, Evangelista I, Cel M, Mazzone A. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021 Oct 1;181(10):1407-1408. https://doi.org/10.1001/jamainternmed.2021.2059.

5. Israel A, Shenhar Y, Green I, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. Vaccines (Basel). 2021;10(1):64. Published 2021 Dec 31. https://doi.org/10.3390/vaccines10010064

6. Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584:115-119

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.